New legislation mandates that 100% of air cargo on passenger aircraft must be screened for explosives by August 2010 (Public Law 110-53 ‘‘Implementing Recommendations of the 9/11 Commission Act of 2007’’). Those responsible for meeting the mandate, such as Freight Forwarders and Indirect Air Carriers, have been facing significant challenges in implementing these requirements and have been looking for innovative technologies to help them achieve this goal.
Glenn D. Bolduc, Implant Sciences' Chief Executive Officer commented “At the urging of air cargo industry leaders, Implant Sciences accelerated the development of the QS-H300 and was ready to respond when the TSA called for the evaluation of new technologies capable of meeting the air cargo screening challenge,” Mr. Bolduc continued, “Implant Sciences is committed to developing advanced anti-terrorism technology in support of these new homeland security measures.”
The QS-H300 is a new Explosives Trace Detection (ETD) system combining several unique technologies for the fast and efficient non-contact screening of packages of any size. These technologies are particularly effective in difficult environments such as those found in air freight facilities. The QS-H300 is easy to use, has very low operating costs, and has been designed to offer effective screening in fast-paced cargo screening operations without disrupting the normal work flow.
Jeff Tehan, Implant Sciences' Vice President of Marketing and Sales said, “We are excited about the opportunity to have the QS-H300 evaluated by the TSA. The evaluation provides a critical qualifying element as we finalize the product development and get closer to market introduction.”
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for the Security, Safety and Defense (SS&D) industries. The Company has developed proprietary technologies used in its commercial portable and bench-top explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that: if the NYSE Amex delists our common stock, it may be extremely difficult to raise capital; if third party credit is unavailable, our working capital could be restricted and we may not be able to borrow capital; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO, 978-752-1700